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Abstract. 
 
Innervation of the neuromuscular junction 
(nmj) affects the stability of acetylcholine receptors 
(AChRs). A neural factor that could affect AChR sta-
bilization was studied using cultured muscle cells since 
they express two distinct populations of AChRs similar 
to those seen at the nmjs of denervated muscle. These 
two AChR populations are (in a ratio of 9 to 1) a rap-
idly degrading population (Rr) with a degradation half-
life of 
 
z
 
1 d and a slowly degrading population (Rs) that 
can alternate between an accelerated form (half-life 
 
z
 
3–5 d) and a stabilized form (half-life 
 
z
 
10 d), depend-
ing upon the state of innervation of the muscle.
Previous studies have shown that elevation of intra-
cellular cAMP can stabilize the Rs, but not the Rr. We 
report here that in cultured rat muscle cells, exogenous 
ATP stabilized the degradation half-life of Rr and pos-
sibly also the Rs. Furthermore, pretreatment with ATP 
caused more stable AChRs to be inserted into the mus-
cle membrane. Thus, in the presence of ATP, the deg-
radation rates of the Rr and Rs overlap. This suggests 
that ATP released from the nerve may play an impor-
tant role in the regulation of AChR degradation. Treat-
ment with either the cAMP analogue dibutyryl-cAMP 
(dB-cAMP) or the calcium mobilizer ryanodine caused 
the ATP-stabilized Rr to accelerate back to a half-life 
of 1 d. Thus, at least three signaling systems (intracellu-
lar cAMP, Ca
 
2
 
1
 
, and extracellular ATP) have the po-
tential to interact with each other in the building of an 
adult neuromuscular junction.
 
T
 
he
 
 metabolic stability of the acetylcholine receptor
(AChR)
 
1
 
 of skeletal muscle is regulated develop-
mentally and is dependent on innervation (for re-
views see Schuetze and Role 1989; Salpeter et al., 1993).
However, the nature of the neural regulation in building
an adult neuromuscular junction (nmj) having stable AChRs
is not yet fully understood. One major source of confusion
is the fact that during critical periods of development or
during the denervation/reinnervation cycle, two distinct
AChR populations with very different inherent degrada-
tion rates and different responses to stabilizing influences
can coexist, interspersed at the neuromuscular junction
(Shyng and Salpeter, 1989, 1990). These two distinct re-
ceptor entities are (
 
a
 
) a rapidly degrading AChR (Rr)
(degradation half-life 
 
z
 
1 d) that is synthesized and ex-
pressed predominantly in embryonic and denervated mus-
cle and (
 
b
 
) a more slowly degrading AChR (Rs) that can
exist in either a stabilized (degradation half-life 
 
z
 
10 d) or
accelerated form (degradation half-life 
 
z
 
3–4 d) and is syn-
thesized and expressed predominantly in adult innervated
muscle. The exact half-lives vary between muscles and be-
tween animal species (Bevan and Steinbach, 1983; Andre-
ose et al., 1993), but the relative effect of different stabiliz-
ing and destabilizing conditions is remarkably consistent.
To date, much more information is available on the regu-
lation of Rs than of Rr degradation. A well-established in-
stance of Rs regulation is its stabilization by either inner-
vation or by intracellular cAMP to the adult degradation
rate of 
 
z
 
10 d (Salpeter et al., 1986; Shyng et al., 1991;
O’Malley et al., 1993; Andreose et al., 1993). Under these
conditions, neither stabilization of Rr to adult degradation
values nor interconversion between the Rr and Rs AChRs
has been observed.
The present paper deals with new observations on the
stabilization of AChRs. We find that under the influence
of ATP, Rr can be stabilized to overlap the Rs degradation
rate. Thus, under certain circumstances, perhaps during
development or reinnervation of denervated muscle, ATP
released from the nerve could stabilize the embryonic Rr
to bridge the time when the Rr are replaced by the adult
Rs. Evidence is also given that the action of ATP may be
mediated by a P2 purinergic receptor. However, the
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1. 
 
Abbreviations used in this paper
 
: 
 
a
 
-BTX, 
 
a
 
-bungarotoxin; AChR, ace-
tylcholine receptor; dB-cAMP, dibutyryl cAMP; nmj, neuromuscular
junction; PLA
 
2
 
, phospholipase A
 
2
 
; Rr, rapidly degrading acetylcholine re-
ceptors; Rs, slowly degrading acetylcholine receptors.
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unique and independent nature of Rr and Rs metabolic
stability is still maintained since, unlike the cAMP stabi-
lized Rs, purine-stabilized Rr are accelerated back to a
faster decay rate by dibutyryl-cAMP (dB-cAMP) as well
as by the Ca
 
2
 
1 
 
activator ryanodine.
These data, plus earlier experimental evidence (for re-
view see Salpeter et al., 1993), have led us to the working
hypothesis that the formation of an adult neuromuscular
junction containing stable AChRs may involve two pro-
cesses. One is a replacement of Rr by Rs, which requires
down regulation of Rr (Andreose et al., 1993) and/or up
regulation of Rs. The second involves posttranslational
modifications of AChRs either during or after insertion
into the sarcolemma. The data presented here indicate
that ATP may mediate one such modification, and, by its
ability to stabilize Rr, ATP may play an important role at a
time when the Rr predominates and the Rr to Rs content
of the muscle is changing. In addition, our data emphasize
the potential interactions between different signaling
pathways involved in the production of a stable AChR
population at the innervated nmj.
 
Materials and Methods
 
Muscle Cell Culture
 
Collagenase-dissociated rat muscle cells were plated in 1.5 ml medium
consisting of 20% FBS and 80% culture medium (10% horse serum, 90%
Dulbecco’s minimum essential medium) and at 3 
 
3
 
 10
 
5
 
 cells/ml onto 35-mm
tissue culture dishes (Corning Glass Works, Corning, NY) coated with a
thin layer of 0.05% Matrigel (Collaborative Biomedical Products,
Waldham, MA) using a previously published method (O’Malley et al.,
1993, 1996). The day of seeding was designated day 1 of culture. On day 2
of culture, the medium was changed to culture medium alone. Drug treat-
ment was initiated on day 4 of culture, after which the culture medium was
changed at daily intervals.
 
Labeling of AChRs with [
 
125
 
I]
 
a
 
-bungarotoxin and 
Estimation of AChR Degradation
 
For experiments in which the effects of drugs were measured on AChRs
already in the membrane, the AChRs were labeled with [
 
125
 
I]
 
a
 
-bungaro-
toxin ([
 
125
 
I]
 
a
 
-BTX) on culture day 4 as described earlier (O’Malley et al.,
1993). In experiments where treatment with drugs preceded [
 
125
 
I]
 
a
 
-BTX
labeling, the AChRs were labeled on culture day 7.
The medium was changed at daily intervals for 14 d after labeling, and
its radioactivity was measured. After the medium was removed for the last
time, the remaining [
 
125
 
I]
 
a
 
-BTX bound to the tissue was recovered by
wiping the culture dish twice with cotton swabs. The loss of AChR during
the sampling period was calculated by summing all the radioactivity re-
leased into the media plus that remaining on the dish at the end of the
sampling period. Calculated residual radioactivity per sample day was
plotted on a semi-logarithmic scale as described previously (Burden, 1977;
Bevan and Steinbach, 1983; Shyng et al., 1991; O’Malley et al., 1993). In a
variant of the procedure used previously (Shyng and Salpeter 1989;
O’Malley et al., 1993), the degradation rate(s) and relative proportions of
the fast and slow components were determined by fitting the logarithmic
decay of labeled receptors to a double exponential using a computer pro-
gram based on the Levenberg-Marquart method (Press et al., 1992). The
use of a double exponential fit to describe the degradative behavior of
acetylcholine receptors in muscle relies on the assumption that the two
components, Rr and Rs, are distinct and that their half-lives remain invari-
ant throughout the observation period. However, in the present study
these assumptions do not always hold, since some Rr were stabilized to
values that overlap those of the Rs (see Results). The double exponential
fitting was nevertheless used for the purpose of providing a description of
the different degradation rates of the AChR populations. However, these
curves cannot necessarily make any definitive claims regarding the rela-
tive content of Rr and Rs in the slow component.
 
Drug Treatment of Cell Cultures
 
Myotubes were treated on alternating on and off cycles (2 h each) with
50 mM ATP (Sigma Chemical Co., St. Louis, MO), supplied by a syringe
pump (Sage model 362; VWR Scientific Products, Bridgeport, NJ) at a
rate of 5 
 
m
 
l/h (250 nmol/h) into the center of a 35-mm dish containing 1 ml
of culture medium to give a potential maximal dose of 500 
 
m
 
M per cycle.
It should be noted that when 1 mM ATP is added to cultures, the media
become slightly acidic, sufficiently so to cause a change in the phenol red
indicator that could be seen by eye. This effect is temporary (presumably
due to enzymatic degradation of the ATP) and is gone within a few hours
of application. No such pH shift was ever seen with syringe application, in-
dicating that ATP did not accumulate and presumably was degraded by
the end of each off cycle. Treatment with ATP was initiated on culture
day 4 either immediately after, or 3 d before, labeling of AChR with [
 
125
 
I]
 
a
 
-
BTX and was maintained throughout the sampling period. In some exper-
iments, dB-cAMP (Sigma Chemical Co.) or ryanodine (Calbiochem, La
Jolla, CA) at final concentrations of 2 mM and 1 
 
m
 
M, respectively, was
added to the culture medium 3 d after the labeling of AChRs and the initi-
ation of syringe application of ATP. Both drugs were then maintained
throughout the experiment. Labeling the AChRs on culture day 4 before
the addition of any drugs allowed the observation of the effects of the
drug treatment on preexisting AChRs.
In other experiments, myotubes were treated on culture day 4 immedi-
ately after [
 
125
 
I]
 
a
 
-BTX labeling with 50 U/ml of phospholipase A
 
2
 
 (Sigma
Chemical Co.), 5 
 
m
 
g/ml melittin (Sigma Chemical Co.), 2 mM dB-cAMP,
or 1 
 
m
 
M ryanodine. In all experiments, control myotubes were labeled at
the same time as those treated with drugs.
 
35
 
S Incorporation and Measurement of Overall
Protein Loss
 
Myotubes were treated on culture day 3 with 10 
 
m
 
l of a 11 mCi/ml 
 
35
 
S-pro-
tein labeling mix (EXPRE
 
35
 
S
 
35
 
S, New England Nuclear, Boston, MA) in
1 ml of culture medium and cultured for a further 24 h. On culture day 4,
they were washed three times with 1 ml Earle’s balanced salt solution, af-
ter which they were cultured in 1 ml of culture medium in the presence of
the test drug at the concentration indicated in the results. The medium
was changed at daily intervals for 14 d and, after the addition of an equal
volume of scintillant (Liquiscint; National Diagnostics, Inc., Manville, NJ),
counted on a beta spectrometer (model LS230; Beckman Instruments,
Fullerton, CA). On the last day of sampling, the medium was removed for
counting, after which the cells were lifted in 1 ml of culture medium using
a rubber policeman before counting. Protein degradation was then deter-
mined in the same manner as that for AChR degradation described above.
 
Results
 
We were concerned that the expression of adenosine deam-
inase by cultured myotubes could minimize the effect of
bath application of purines requiring high doses of these
drugs. To circumvent this problem, ATP was applied via a
syringe pump in a cyclical manner (2 h continuous release
followed by 2 h with no release) to allow for enzymatic re-
moval of the drug between cycles.
Fig. 1 compares the AChR degradation curves of con-
trol and ATP-treated muscle cultures. The data is ana-
lyzed by fitting a two-component exponential curve to the
experimental data as given in Materials and Methods.
AChRs from untreated control myotubes, which were la-
beled with [
 
125
 
I]
 
a
 
-BTX on culture day 4, behaved as previ-
ously reported (O’Malley et al., 1993), but with a slightly
slower slow component. They degraded in a biphasic man-
ner with the majority (90%) of the AChRs decaying with
half-lives of 1 d (representing the Rr AChR) and the re-
maining (10%) with a half-life of 4.2 d (representing the
Rs AChRs). When muscle cells were treated with ATP af-
ter the AChRs were labeled with [
 
125
 
I]
 
a
 
-BTX, a biphasic
degradation of AChRs was again obtained. However, in 
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the ATP-treated cultures, the relative content of the slow
component was almost doubled, and the half-life of the
slow component stabilized to 11 d (Fig. 1). Preliminary ex-
periments showed a stabilization of AChRs after treating
the cells with adenosine but not with the adenosine degra-
dation product inosine (data not shown). Since the AChRs
were labeled with [
 
125
 
I]
 
a
 
-BTX before treatment with ATP,
the increased slow component could not reflect newly in-
serted AChRs and must indicate a stabilization of the pre-
existing Rr. As indicated in Materials and Methods, the
use of the two-component exponential decay curve allows
the determination of the relative content and the degrada-
tion rates of two independent populations of AChRs.
However, in the case where there is stabilization of the
degradation of the fast component, the two-component
curve contains some uncertainties in interpretation. There
could be a very early stabilization of a small fraction of the
fast component, which would be most analogous to the
two population case. Alternatively, there could be a de-
layed stabilization of all the remaining fast component or a
gradual stabilization throughout the assay period.
In the last two cases, the assumption that the Rr half-life
is the same throughout the degradation period no longer
holds, and the disclaimer regarding the ability of obtaining
an accurate assessment of the relative content of stabilized
Rr would apply. Since we do not know which case is true
in the present study, we can only claim unequivocally that
because of the increase in the slow component when AChRs
were prelabeled with [
 
125
 
I]
 
a
 
-BTX, a stabilization of some
Rr must have occurred.
The question of whether the Rs are also stabilized by
ATP arises. With the analysis used in this study, it is not
possible to answer this question since the total amount of
Rs is normally small, and when interspersed with the stabi-
lized Rr, a difference between a half-life of 3 and 10 d is
difficult to resolve. Explicitly, we cannot distinguish be-
tween a three-component curve in the ratio of half-lives of
1:3:10 d and a two-component curve.
To test if the action of the purines was mediated by a P2
class purinergic receptor, as has been previously reported
for other effects of ATP on muscle (Haggblad & Heilbronn,
1988; Fu and Poo, 1991), we mimicked P2 receptor activity
by treating myotubes with either phospholipase A
 
2
 
 (PLA
 
2
 
)
or a PLA
 
2
 
 activator melittin. AChRs from myotubes that
were treated with PLA
 
2
 
 after [
 
125
 
I]
 
a
 
-BTX labeling de-
cayed with a double exponential of 1 and 8 d with the slow
component constituting 33% of the AChR population
(Fig. 2). A similar result was obtained from cells treated
with 5 
 
m
 
g/ml melittin, in which the slow component with a
half-life of 10 d constituted 58% of the receptor popula-
tion (Fig. 2). Indeed, of all the putative second messengers
associated with purinergic signal transduction that were
tested (PLA2 [Fig. 2], calcium and cAMP [Fig. 6], and
cGMP [data not shown]), only activators of the PLA
 
2
 
 path-
way mimicked the effect of ATP on AChR stabilization.
To determine whether agents that stabilized AChRs had
a general effect on total protein degradation, loss of 
 
35
 
S-
labeled protein was measured in the presence of dB-
cAMP, PLA
 
2
 
, melittin, and ATP at the concentrations
used in this study. No significant difference was observed
with any of these treatments relative to controls (Fig. 3).
Thus, the stabilizing effect of ATP, PLA
 
2
 
, melittin, and
dB-cAMP appear to be specific to the AChR.
If muscle cells were pretreated with ATP from day 4 to
7, and the AChRs were labeled with [
 
125
 
I]
 
a
 
-BTX on cul-
ture day 7, the proportion of slowly degrading receptors
was 34% of the total AChR population with a half-life of
12 d. To eliminate any influence of culture age on AChR
degradation, a control group was labeled on culture day 7
without ATP treatment. The proportion of slowly degrad-
ing AChRs remained similar to that in control cells la-
beled on culture day 4 (Fig. 4). These data indicate that
AChRs inserted into the muscle membrane in the pres-
ence of ATP are more likely to be stable.
We found, however, that the purine-induced stabilization
Figure 1. ATP stabilizes preexisting AChRs. Acetylcholine re-
ceptors were labeled with [125I]a-BTX before muscle cells were
treated cyclically with a potential maximal dose of 500 mM ATP
per cycle. The degradation curves of the AChRs is the best fit of
two decay rates. When the experimental data extends far enough
so as not to include significant input from the fast component, the
degradation curves consist almost exclusively of the slow compo-
nent. The slopes of the two components on a semi-logarithmic
plot give their half-lives. Provided the assumptions underlying
the use of two-component exponential as described in Materials
and Methods is fulfilled, the intercept of the slow component
with the y-axis can then be used to estimate the fraction of the to-
tal receptor population that constitutes the slow component at
day 0. The 9% of total AChRs constituting the slow component
of controls (s) decayed with a half-life of 4.2 d, while the slow
component of the ATP-treated cells (m) (20% of the total) de-
cayed with a half-life of 11.1 d. The double exponential curve fit-
ted to the ATP data (solid line) assumes that the Rs was also sta-
bilized by ATP. To test whether it is possible to determine if the
Rs were not stabilized, a single exponential decay of 4.2 d consti-
tuting 9% of the total AChRs (the half-life of the Rs in the con-
trols) was subtracted from the ATP data, and a double exponen-
tial was fitted to the remaining values. Half-lives of 1.2 (80% of
total) and 14.0 d (11% of total) were obtained. Addition of the
three components gave a triple exponential fit that was identical
in shape to the double exponential fit shown. Thus, it is not possi-
ble with this data to state whether the Rs was also stabilized. Val-
ues are mean 6 SEM of seven experiments. 
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appears different from that reported for the stabilization
of Rs (to a half-life of 
 
z
 
10 d) by cAMP analogues (Shyng
et al., 1991; O’Malley et al., 1993). If the ATP-stabilized
AChRs were treated with 2 mM dB-cAMP in the contin-
ued presence of ATP, the stabilization was reversed, and
the profile of the curve inclined towards that of control
cultures (Fig. 5 
 
a
 
). A similar result was seen with 1 
 
m
 
M ryano-
dine (Fig. 5 
 
b
 
). Lower concentrations of the cAMP analogue
or the calcium mobilizer (1 mM or 100 nM, respectively)
were not able to reverse the ATP-induced stabilization of
these AChRs. However, in preliminary experiments, such
lower concentrations cAMP or ryanodine did reverse AChR
stabilization by bath-applied purines (data not shown).
Thus dB-cAMP and ryanodine reversal of purine stabiliza-
tion appears to be critically dependent on either the con-
centration or the periodicity of the purine signal.
The acceleration of ATP-stabilized AChRs by both dB-
cAMP and ryanodine is particularly interesting since both
compounds behave very differently when applied to con-
trol cells. We previously reported that treatment of muscle
cells in culture with 1 mM dB-cAMP results in the stabili-
zation of preexisting Rs to a half-life of 
 
z
 
10 d (O’Malley
et al., 1993) without altering the degradation rate of the
Rr. We obtained a similar result in the present study (Fig. 6).
In addition, when control AChRs are treated with ryano-
dine, little effect on AChR degradation is seen, although a
slight acceleration of the AChR degradation may occur.
(Preliminary results show that ryanodine causes a signifi-
cant increase in cytoplasmic calcium levels within 24 h of
application [O’Malley, J.P., W.R. Zipfell, and M.M. Salpeter,
manuscript in preparation].)
 
Discussion
 
Extensive literature has established that the Rr and Rs
AChRs are distinct molecules that do not interconvert (for
review see Salpeter et al., 1993). The data from the present
study confirm this conclusion and add a complexity that
helps clarify existing information on the construction of an
adult nmj with stable AChRs. The information from ear-
lier studies showed that both Rs and Rr can coexist at the
nmj (as, for instance, after denervation; Shyng and Sal-
peter, 1989, 1990) and in tissue culture cells (O’Malley et al.,
1993) while degrading simultaneously, each at its own rate.
It was also shown that in both denervated junctions and
tissue culture cells, stabilization of Rs can be accomplished
by elevating cAMP (O’Malley et al., 1993; Xu and Sal-
peter, 1995) without affecting the degradation rate of na-
ive Rr. Thus, the mechanisms of stabilization are clearly
distinct for Rs and Rr.
In the present paper, we report the novel observation
that in tissue cultured muscle cells, Rr AChRs can be sta-
bilized by exogenously applied purines and that this stabi-
lization is reversed by the cAMP analogue dB-cAMP and
by the calcium activator ryanodine. Previous reports that
Rr can be stabilized by electrical stimulation (Rotzler and
Brenner, 1990) have been disputed (Andreose et al., 1993),
and the report that calcium can stabilize AChRs (Rotzler
et al., 1991) is not confirmed by our own observations
(O’Malley, J.P., W.R. Zipfell, and M.M. Salpeter, manu-
script in preparation). However there is additional new ev-
idence that Rr stabilization may be present in vivo during
reinnervation (Salpeter, M.M., and M. Szabo, manuscript
Figure 2. Melittin or PLA2 stabilize preexisting AChRs. Acetyl-
choline receptors were labeled with [125I]a-BTX before muscle
cells were treated with 5 mg/ml melittin or 50 U of PLA2. The
degradation curves of the AChRs is the best fit of two decay
rates. The slow component of controls (s) (13% of total) de-
cayed with a half-life of 4.0 d, while the slow component of melit-
tin- (j) (58% of total) or PLA2- (m) (32.8% of total) treated cells
decayed with a half-life of 9.73 and 7.6 d, respectively. Values are
mean 6 SEM from four experiments.
Figure 3. Treatments that slow AChR degradation do not affect
total protein turnover. Myotubes were treated for 24 h with 35S-
protein labeling mix, after which they were washed and cultured
in the presence of 2 mM dB-cAMP (j), 50 U PLA2 (d), 5 mg/ml
melittin (n), or 500 nmol/cycle ATP (m). Parallel control (s)
cultures were labeled with 35S but not treated with drugs. Me-
dium was changed at daily intervals, and after counting, the ra-
dioactivity degradation profiles were constructed as described in
Materials and Methods. Values are mean 6 SEM from three ex-
periments. 
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in preparation). Purines may also stabilize the Rs, but such
an effect is difficult to determine in our present study,
given the small relative content of Rs in cultured muscle
cells (Figs. 1 and 4) and the difficulty, when the t1/2 values
are similar, in distinguishing a three-component (if the Rs
was not stabilized) from a two-component (if the Rs was
stabilized to the same half-life as the stable Rr) curve.
However, a residual slow component is seen in cultures
where ATP stabilization of Rr is reversed by cAMP or cal-
cium. Such a residual slow component suggests that an
ATP stabilization of Rs may have been present and was
not reversed by the dB-cAMP or ryanodine at the concen-
trations used (Fig. 5). Thus, under special circumstances
the degradation rates and stabilization mechanisms of Rr
and Rs could overlap.
Because of when they are expressed in vivo, the Rs is
the adult and thus an 
 
e
 
-containing AChR, while the Rr is
the embryonic and thus a 
 
g
 
-containing AChR (Mishina et al.,
1986; Gu and Hall, 1988; Brenner et al., 1990; Duclert and
Changeux, 1995; Missias et al., 1996). However, contradic-
tory data in nonmuscle systems expressing AChRs with
different subunits (Gu et al., 1990; Jaywickreme and Clau-
dio, 1994; Kopta and Steinbach, 1994; Liu et al., 1994) do
not resolve the question of whether the different stabiliza-
tion mechanisms of the Rs and Rr depend on the presence
of the gamma versus epsilon subunits. However, a recent
study (Sala, C., J.P. O’Malley, R. Xu, G. Fumagalli, and
M.M. Salpeter, manuscript in preparation) shows that the
 
e
 
 AChR is of the slowly degrading Rs population.
The concentration of ATP applied in the syringe appli-
cation was derived empirically as being the lowest concen-
tration of ATP capable of slowing the degradation of a pre-
existing AChR population. Thus, it represents a threshold
dose. Higher concentrations of ATP did indeed induce
greater stabilization effects (data not shown). However,
because protein turnover is dependent upon the metabolic
state of the cells and purines have been reported to affect
the metabolic rate of muscle in vivo, we chose to use a
dose that we determined to have no nonspecific effect on
total protein turnover (Fig. 3).
To determine which purinergic receptor system may
mediate the ATP effect on AChR stability, we tested sec-
ond messengers reported to be elevated by purinergic re-
ceptor activation. Only factors that upregulated the activ-
ity of the PLA
 
2
 
 pathway mimicked the effects of ATP on
AChR stabilization (Fig. 2). Thus, it is not unreasonable to
suggest that the effect of ATP on AChR stability is proba-
bly mediated through a P2 purinergic receptor via PLA
 
2
 
.
This conclusion is consistent with reports of the presence
of P2 purinergic receptors in muscle cells (Haggblad and
Heilbronn, 1988). In addition, ATP, in the range of 100 
 
m
 
m
to 1 mM, potentiates spontaneous synaptic currents in 
 
Xe-
nopus
 
 nerve–muscle cell cultures (Fu and Poo, 1991) via a
G protein–linked production of arachidonic acid by PLA
 
2
 
(Harish and Poo, 1992). In the present study, PLA
 
2
 
 was
able to stabilize AChRs when applied exogenously. Thus,
unless the exogenous PLA
 
2
 
 added to myotubes was incor-
porated into their membrane, the site for PLA
 
2
 
 cleavage
must be extracellular. This may prove critical in determin-
ing the molecular basis of the purinergic stabilizing activity.
The ability of adenosine to stabilize AChRs with appar-
ently equal efficiency to ATP is puzzling. Normally, puri-
nergic receptors can be pharmacologically differentiated
on the basis of preferred affinity for either AMP and aden-
osine (P1 class receptor) or ATP and ADP (P2 class recep-
tor). However, at sufficiently high doses, adenosine may
still activate a P2 class receptor (Gordon and Martin, 1983;
Gordon, 1986).
The cultured muscle cells exhibited spontaneous contrac-
tile activity after culture day 5. Muscle contraction would
be expected to be accompanied by transient elevation of
intracellular calcium, which might then be expected to re-
verse the effect of ATP-induced AChR stabilization. How-
ever, ATP stabilization of AChRs is maintained through-
out this period. This implies either that calcium released
from intracellular sources does not affect the transduction
of the ATP signal or that calcium is not elevated in sponta-
neous cultures to the same level as in ryanodine-treated
cultures and is thus not sufficient to reverse the effect of
ATP. It has been suggested that calcium entering the cell
from extracellular sources plays an important role in sup-
pressing AChR expression (Walke et al., 1994). Such a re-
lationship between the site of calcium entry may also exist
for AChR stability. However, ryanodine can also suppress
AChR expression (Rubin, 1985). Also, our unpublished
data seems to be able to mimic the effects of extracellular
Ca
 
2
 
1
 
 influx by simply elevating intracellular calcium to a
level that is effective, regardless of its site of release or entry.
The results in this report demonstrate that the action of
calcium and cAMP on AChR stability are dependent upon
the condition of the myotube before the initiation of these
Figure 4. Chronic pretreatment with ATP increases the propor-
tion of slowly degrading AChRs. Treatment with ATP was initi-
ated on culture day 4, and AChRs were labeled with [125I]a-BTX
3 d later. The degradation curves of both control and ATP-treated
cultures were fitted with a double exponential decay. For both
the controls (s) and ATP- (m) treated cells, the solid line is the
sum of the two exponentials. In addition to slowing the rate of
degradation of the slow component, ATP treatment caused an in-
crease in the proportion of slowly degrading AChRs from 9% in
controls to 33% in ATP-treated cells. Values are mean 6 SEM
from five experiments.The Journal of Cell Biology, Volume 138, 1997 164
signals. In naive muscle cells calcium mobilization with ry-
anodine has little effect on AChR degradation, while cAMP
analogues induce a stabilizing influence only on the Rs
AChRs. However, elevation of calcium or cAMP results in
a destabilization of an ATP-stabilized AChR population.
These observations illustrate that, unless the second mes-
senger state of the muscle is known, it is difficult to predict
the action of any agent on the degradation behavior of
AChRs. It may be that the complicated interaction be-
tween the three signaling pathways (Ca21, cAMP, and
ATP) accounts for the overall responses of AChRs to sig-
nals at different stages of development and innervation.
The relationship between Rr AChR stabilization by ATP
and the action of Ca21 provides an interesting complexity.
The preliminary observation that more calcium mobilizer
is required to reverse the effect of syringe pump than bath-
applied ATP suggests that the calcium and ATP signaling
pathways may compete with each other. A time when such
a competition between ATP and Ca21 on AChR stability
may be important is during the period of synapse elimina-
tion, when embryonic AChRs are still present. It has been
reported that the loss of synaptic contact is preceded by a
loss of AChRs in reinnervating (Rich and Lichtman, 1989)
and developing (Balice-Gordon and Lichtman, 1993) and
adult muscle (Balice-Gordon and Lichtman, 1994). Thus,
it appears that the maintenance of an AChR population in
the postsynaptic membrane is essential for a neuron to
maintain contact. If, during the period of synapse elimina-
tion, the calcium signal associated with AChR activation is
sufficiently large and diffuse, an active neuron may be able
to contribute to the destabilization of the AChRs of an ad-
jacent neuron while restabilizing its own AChR population
by the release of ATP. This model requires that the ATP
stabilization effect is confined to the region immediately
below the point of release and that the calcium destabiliz-
ing activity spread to adjacent sites, and that the pharma-
cological relationship between calcium and ATP be compet-
itive. If true, activity-dependent (Hebbian) competition
between  neurons could result. Although highly hypotheti-
cal, such conjectures warrant further experiments.
The fact that Rr can be stabilized under the influence
of ATP provides a possible resolution to a lingering con-
troversy. It has been argued that AChR stability is inde-
pendent of subunit composition since AChRs become sta-
bilized soon after innervation, before the adult epsilon
subunit becomes predominant (for review see Hall and
Sanes, 1993). Our data provide a possible missing link in
the events occurring during the development of a stable
adult nmj. The ingrowing nerve, by releasing ATP, could
stabilize the embryonic or Rr AChRs, thus providing a
bridging degradation rate to the adult receptors. Recent
data (Salpeter, M.M., and M. Szabo, manuscript in prepa-
ration) has strengthened this conjecture by showing that
AChRs inserted during reinnervation of denervated mus-
cle have a partially stabilized half-life of 3–4 d while most
likely being g-containing. Such a bridging degradation
value could prevent a dip in AChR density that could oc-
cur if the rapidly degrading embryonic receptors (Rr)
were directly replaced by slowly degrading adult receptors
(Rs). One possible scenario for the events leading to the
establishment of a stable neuromuscular junction without
a major loss of AChR number during critical periods of
Figure 5. ATP-induced stabilization of Rr is reversed by both dB-cAMP (a) and ryanodine (b). AChRs were labeled with [125I]a-BTX,
and ATP treatment (m) was initiated on culture day 4. 3 d later, some ATP-treated plates were treated with 2 mM dB-cAMP or 1 mM
ryanodine in combination with the ATP (n). Some untreated control cultures (s) were also labeled on culture day 4. The degradation
curves of control and ATP-treated cells gave double exponential fits as also seen in Fig. 1. When ATP is followed by treatment with dB-
cAMP (a) or ryanodine (b), a distinct acceleration of the Rr AChR towards the control curve is seen. From sample day 8, these curves
begin again to diverge away from control curves, suggesting that the Rs may not have been accelerated by these treatments. Values are
the mean 6 SEM of four experiments.O’Malley et al. Acetylcholine Receptor Stabilization by ATP 165
development or reinnervation could involve an early puri-
nergic stabilization of Rr when AChRs are still g-contain-
ing, followed by a down regulation of Rr synthesis induced
by muscle activity (for review see Hall and Sanes, 1993).
The Rr would then be replaced by stable Rs, presumably
stabilized by cAMP or some other as yet unidentified neu-
ral factor.
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